Carol Moreno - Concepedia

Author

Carol Moreno

Also Known As

B Semans, C Moreno, C. Cámara Moreno, C. Moreno, Carla Caballero Moreno, Carol Moreno, Josep Nomdedeu, Luca Castagna, Moreno, C., Moreno, Christophe

381

Publications

13.6K

Citations

H-Index

126

Concepts

All Affiliations

Hospital de Sant Pau Pharmacyclics (United States)Universitat Autònoma de Barcelona Medical College of Wisconsin AbbVie (United States)

About

Carol Moreno is an author at Hospital de Sant Pau specializing in medicine, health sciences, and hematology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	25	41	3.2K
2	Health Sciences	16	20	2.4K
3	Public Health	4	4	195
4	Biochemistry	1	1	15
5	Biology	1	1	14

Carol Moreno

115

Publications

11.4K

Citations

H-Index

Page 1

	Year	Citations
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia John C. Byrd, Jennifer R. Brown, Susan O’Brien, New England Journal of Medicine	2014	1.6K
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial Carol Moreno, Richard Greil, Fatih Demırkan, The Lancet Oncology Hematological MalignancyLymphoid NeoplasiaOncologyChronic Lymphocytic LeukaemiaImmunology	2018	536
Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: pathogenetic implications and clinical correlations Chrysoula Belessi, Carol Moreno, Myriam Boudjograh, Blood	2006	528
Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma Talha Munir, Jennifer R. Brown, Susan O’Brien, American Journal of Hematology	2019	451
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study Jan A. Burger, Paul M. Barr, Tadeusz Robak, Leukemia	2019	447
International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia Andy C. Rawstron, Neus Villamor, Matthias Ritgen, Leukemia Hematological MalignancyLymphoid NeoplasiaChronic Lymphocytic LeukaemiaMedicineMalignant Blood Disorder	2007	396
Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis Fiona Murray, Nikos Darzentas, Anastasia Hadzidimitriou, Blood	2007	328
Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats Ming Yu, Carol Moreno, Kimberly M. Hoagland, Journal of Hypertension	2003	275
Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia Paul M. Barr, Carolyn Owen, Tadeusz Robak, Blood Advances Ibrutinib Vs 9Chronic Lymphocytic LeukemiaImmunologyPharmacotherapyFirst-line Ibrutinib Treatment	2022	246
Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab John C. Byrd, Peter Hillmen, Susan O’Brien, Blood	2019	238

Page 1